Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 23;12(1):6687.
doi: 10.1038/s41598-022-07741-z.

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Collaborators, Affiliations

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Chiara Agrati et al. Sci Rep. .

Abstract

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
(A) Humoral response 5 (T5w) and 12 (T12w) weeks after vaccination. SARS-CoV-2 specific anti-N, anti-RBD and neutralizing Abs were quantified in sera samples at both time points. Anti-N-IgG are expressed as index values S/CO and values ≥ 1.4 are considered positive; Anti-RBD-IgG are expressed as Binding Arbitrary Units (BAU)/mL and values ≥ 7.1 are considered positive; neutralizing Abs are expressed as the highest serum reciprocal of dilution inhibiting at least 90% of the cytopathic effect (MNA90), values ≥ 10 are considered positive. (B) Cell-mediated immune response 5 (T5w) and 12 (T12w) weeks after vaccination. Cytokines (IFN-γ, TNF-α, IL-2) were quantified in stimulated blood samples at both time points and showed after subtracting the background. Dashed line identify the cut-off of each test calculated as the mean  ± 2SEM of 55 anti-S and anti-N negative HCW before vaccination. Differences between the median in T5w and T12w were calculated by paired t test. ****p < 0.0001; *p < 0.5. (C) Correlation between humoral and cell-mediated immune response 12 (T12w) weeks after vaccination. Correlations within humoral levels (anti-RBD and MNA90), within cell-mediated response (IFN-γ, TNF-α and IL-2) and across humoral and cell-mediated immunity (anti-RBD and IFN-γ, TNF-α and IL-2) are shown. Correlation was analyzed by Spearmen test. Comparison of medians across groups were evaluated by Wilcoxon test for pairwise comparisons. Correlations between assays were assessed by non-parametric Spearman's rank tests. A 2-sided P value < 0.05 was considered statistically significant.

References

    1. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Thompson MG, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:495–500. doi: 10.15585/mmwr.mm7013e3. - DOI - PMC - PubMed
    1. Angyal, A. et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: A multicentre, prospective, observational cohort study. SSRN: https://ssrn.com/abstract=3812375 or 10.2139/ssrn.3812375. - PubMed
    1. Moderbacher CR, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012. doi: 10.1016/j.cell.2020.09.038. - DOI - PMC - PubMed
    1. Dan JM, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(587):eabf4063. doi: 10.1126/science.abf4063. - DOI - PMC - PubMed

Publication types